Chembio Diagnostics received approval of Zika, Dengue and Chikungunya point-of-care multiplex test by Brazil’s Health Regulatory Agency
On Apr. 9, 2019, Chembio Diagnostics announced the approval of its DPP Zika/Dengue/Chikungunya System by Agencia Nacional de Vigilancia Sanitaria (ANVISA), Brazilis health regulatory agency, in collaboration with Bio-Manguinhos/Fiocruz.
Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance.
Tags:
Source: Chembio Diagnostics
Credit:
